518 related articles for article (PubMed ID: 15846258)
21. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.
Ray KK; Morrow DA; Gibson CM; Murphy S; Antman EM; Braunwald E
Eur Heart J; 2005 Mar; 26(5):440-6. PubMed ID: 15673542
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
Murphy SA; Gibson CM; Morrow DA; Van de Werf F; Menown IB; Goodman SG; Mahaffey KW; Cohen M; McCabe CH; Antman EM; Braunwald E
Eur Heart J; 2007 Sep; 28(17):2077-86. PubMed ID: 17600038
[TBL] [Abstract][Full Text] [Related]
23. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
De Luca G; Marino P
Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
[TBL] [Abstract][Full Text] [Related]
24. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
[TBL] [Abstract][Full Text] [Related]
25. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
[TBL] [Abstract][Full Text] [Related]
26. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
[TBL] [Abstract][Full Text] [Related]
27. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
Cohen M; Mahaffey KW; Pieper K; Pollack CV; Antman EM; Hoekstra J; Goodman SG; Langer A; Col JJ; White HD; Califf RM; Ferguson JJ;
J Am Coll Cardiol; 2006 Oct; 48(7):1346-54. PubMed ID: 17010793
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
Petersen JL; Mahaffey KW; Hasselblad V; Antman EM; Cohen M; Goodman SG; Langer A; Blazing MA; Le-Moigne-Amrani A; de Lemos JA; Nessel CC; Harrington RA; Ferguson JJ; Braunwald E; Califf RM
JAMA; 2004 Jul; 292(1):89-96. PubMed ID: 15238596
[TBL] [Abstract][Full Text] [Related]
29. Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction.
Schwarz AK; Zeymer U
Future Cardiol; 2009 Jan; 5(1):43-9. PubMed ID: 19371202
[TBL] [Abstract][Full Text] [Related]
30. ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.
Thomas D; Giugliano RP
J Thromb Thrombolysis; 2009 Jan; 27(1):1-10. PubMed ID: 18931978
[TBL] [Abstract][Full Text] [Related]
31. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
Petersen JL; Mahaffey KW; Becker RC; Goodman SG; Kleiman NS; Marian AJ; Stone GW; Lansky AJ; Lincoff AM; Hazen SL; Nessel CC; Toro-Figueroa L; Tate L; Reist CJ; Cohen M; Califf RM; Ferguson JJ;
Am Heart J; 2004 Aug; 148(2):269-76. PubMed ID: 15308996
[TBL] [Abstract][Full Text] [Related]
32. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.
Antman EM; Cohen M; McCabe C; Goodman SG; Murphy SA; Braunwald E;
Eur Heart J; 2002 Feb; 23(4):308-14. PubMed ID: 11812067
[TBL] [Abstract][Full Text] [Related]
33. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction.
Mega JL; Morrow DA; Ostör E; Dorobantu M; Qin J; Antman EM; Braunwald E
Circulation; 2007 Jun; 115(22):2822-8. PubMed ID: 17515461
[TBL] [Abstract][Full Text] [Related]
34. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
Antman EM
Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449
[TBL] [Abstract][Full Text] [Related]
35. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
Eikelboom JW; Quinlan DJ; Mehta SR; Turpie AG; Menown IB; Yusuf S
Circulation; 2005 Dec; 112(25):3855-67. PubMed ID: 16344381
[TBL] [Abstract][Full Text] [Related]
36. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25.
White HD; Braunwald E; Murphy SA; Jacob AJ; Gotcheva N; Polonetsky L; Antman EM
Eur Heart J; 2007 May; 28(9):1066-71. PubMed ID: 17456482
[TBL] [Abstract][Full Text] [Related]
37. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2).
Andersen HR; Nielsen TT; Vesterlund T; Grande P; Abildgaard U; Thayssen P; Pedersen F; Mortensen LS;
Am Heart J; 2003 Aug; 146(2):234-41. PubMed ID: 12891190
[TBL] [Abstract][Full Text] [Related]
38. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Antman EM; McCabe CH; Gurfinkel EP; Turpie AG; Bernink PJ; Salein D; Bayes De Luna A; Fox K; Lablanche JM; Radley D; Premmereur J; Braunwald E
Circulation; 1999 Oct; 100(15):1593-601. PubMed ID: 10517729
[TBL] [Abstract][Full Text] [Related]
39. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
[TBL] [Abstract][Full Text] [Related]
40. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
Zeymer U; Gitt A; Jünger C; Koeth O; Zahn R; Wienbergen H; Gottwik M; Senges J;
Am J Cardiol; 2006 Jul; 98(1):19-22. PubMed ID: 16784913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
